
## Justin A Mariani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6837402/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prescription trends and costs of diabetes medications in Australia between 2003 and 2019: an analysis and review of the literature. Internal Medicine Journal, 2022, 52, 841-847.	0.8	5
2	Characterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients. JACC Basic To Translational Science, 2022, 7, 116-127.	4.1	20
3	Prediction of Pacemaker Requirement in Patients With Unexplained Syncope: The DROP Score. Heart Lung and Circulation, 2022, 31, 999-1005.	0.4	3
4	Physiologic Insights Into Long COVID Breathlessness. Circulation: Heart Failure, 2022, 15, 101161CIRCHEARTFAILURE121009346.	3.9	0
5	Impact of device length on electrogram sensing in miniaturized insertable cardiac monitors. Journal of Electrocardiology, 2022, 73, 42-48.	0.9	7
6	A prospective <scp>STudy</scp> using <scp>invAsive</scp> haemodynamic measurements <scp>foLLowing</scp> catheter ablation for <scp>AF</scp> and early <scp>HFpEF</scp> : <scp>STALL AFâ€HFpEF</scp> . European Journal of Heart Failure, 2021, 23, 785-796.	7.1	43
7	Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology. Journal of the American Heart Association, 2021, 10, e021584.	3.7	12
8	Driving with cardiac devices in Australia. Does a review of recent evidence prompt a change in guidelines?. Internal Medicine Journal, 2020, 50, 271-277.	0.8	0
9	The prognostic significance of chronotropic incompetence in patients with severe left ventricular systolic function referred for cardiac transplant assessment. European Journal of Preventive Cardiology, 2020, 27, 328-330.	1.8	1
10	Increased Incidence of Noise in the Tendril Pacemaker Lead Detected via Remote Monitoring. Heart Lung and Circulation, 2020, 29, 936-939.	0.4	6
11	Non-invasive blood pressure monitoring underestimates hypertensive response to exercise in suspected heart failure with preserved ejection fraction. European Journal of Preventive Cardiology, 2020, 27, 2180-2182.	1.8	1
12	Contemporary trends in antiplatelet prescription in Australia. Journal of Pharmacy Practice and Research, 2020, 50, 366-368.	0.8	0
13	Identification of physiologic treatment targets with favourable haemodynamic consequences in heart failure with preserved ejection fraction. ESC Heart Failure, 2020, 7, 3685-3693.	3.1	9
14	Position Statement on the Management of Cardiac Electrophysiology and Cardiac Implantable Electronic Devices in Australia During the COVID-19 Pandemic: A Living Document. Heart Lung and Circulation, 2020, 29, e57-e68.	0.4	25
15	Rural and Remote Cardiology During the COVID-19 Pandemic: Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement. Heart Lung and Circulation, 2020, 29, e88-e93.	0.4	25
16	Miniaturized implantable cardiac monitor with a long sensing vector (BIOMONITOR III): Insertion procedure assessment, sensing performance, and home monitoring transmission success. Journal of Electrocardiology, 2020, 60, 118-125.	0.9	23
17	Impact of Individual Patient Profiles on Adherence to Guideline Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction: VCOR-HF Study. Heart Lung and Circulation, 2020, 29, 1782-1789.	0.4	4
18	The effect of parity on exercise physiology in women with heart failure with preserved ejection fraction. ESC Heart Failure, 2020, 7, 214-223.	3.1	3

#	Article	IF	CITATIONS
19	A Retrospective Evaluation of Risk of Peripartum Cardiac Dysfunction in Survivors of Childhood, Adolescent and Young Adult Malignancies. Cancers, 2019, 11, 1046.	3.7	11
20	Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2019, 21, 495-505.	7.1	108
21	Outcomes of anemic patients presenting with acute coronary syndrome: An analysis of the Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events. Clinical Cardiology, 2019, 42, 791-796.	1.8	8
22	SEX DIFFERENCES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: AN INVASIVE HEMODYNAMIC ANALYSIS. Journal of the American College of Cardiology, 2019, 73, 921.	2.8	1
23	Sex Differences in Heart Failure WithÂPreserved Ejection FractionÂPathophysiology. JACC: Heart Failure, 2019, 7, 239-249.	4.1	82
24	Mind the Gap: Mismatches Between Clinicians and Patients in Heart Failure Medication Management. Cardiovascular Drugs and Therapy, 2018, 32, 37-46.	2.6	4
25	Implantable cardioverter defibrillator knowledge and end-of-life device deactivation: A cross-sectional survey. Palliative Medicine, 2018, 32, 156-163.	3.1	14
26	Trends in outpatient antiâ€arrhythmic prescriptions for atrial fibrillation and left atrial ablation in Australia: 1997–2016. Internal Medicine Journal, 2018, 48, 427-432.	0.8	6
27	Biatrial Electrical and Structural AtrialÂChanges in Heart Failure. JACC: Clinical Electrophysiology, 2018, 4, 87-96.	3.2	18
28	Regression of Diffuse Ventricular FibrosisÂFollowing Restoration of SinusÂRhythm With Catheter Ablation inÂPatients With Atrial Fibrillation andÂSystolic Dysfunction. JACC: Clinical Electrophysiology, 2018, 4, 999-1007.	3.2	39
29	Absence of late gadolinium enhancement on cardiac magnetic resonance imaging in ventricular fibrillation and nonischemic cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1109-1115.	1.2	6
30	Cardiac implantable electronic device hematomas: Risk factors and effect of prophylactic pressure bandaging. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 857-867.	1.2	4
31	Caudal fluoroscopy to guide venous access for pacemaker device implantation: should this now be standard practice?. Heart Asia, 2017, 9, 68-69.	1.1	5
32	Hemodynamic Profile of Patients With Heart Failure and Preserved Ejection Fraction Vary by Age. Journal of the American Heart Association, 2017, 6, .	3.7	13
33	Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction. Journal of the American College of Cardiology, 2017, 70, 1949-1961.	2.8	428
34	A comparison of the electrophysiologic and electroanatomic characteristics between the right and left atrium in persistent atrial fibrillation: Is the right atrium a window into the left?. Journal of Cardiovascular Electrophysiology, 2017, 28, 1109-1116.	1.7	22
35	Determining the Optimal Dose of Adenosine for Unmasking Dormant Pulmonary Vein Conduction Following Atrial Fibrillation Ablation: Electrophysiological and Hemodynamic Assessment. DORMANTâ€AF Study. Journal of Cardiovascular Electrophysiology, 2017, 28, 13-22.	1.7	7
36	An overlooked case of pacemaker-related heart failure. Journal of Animal Science and Technology, 2017, 4, K57-K60.	2.5	2

#	Article	IF	CITATIONS
37	Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment NaÃ <sup>-</sup> ve Type 2 Diabetes following Equivalent Weight Loss. Frontiers in Physiology, 2016, 7, 516.	2.8	20
38	The Impact of Known Heart Disease on Longâ€Term Outcomes of Catheter Ablation in Patients with Atrial Fibrillation and Left Ventricular Systolic Dysfunction: A Multicenter International Study. Journal of Cardiovascular Electrophysiology, 2016, 27, 281-289.	1.7	25
39	Cardiac resynchronisation therapy in 2015: keeping up with the pace. Internal Medicine Journal, 2016, 46, 255-265.	0.8	1
40	Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2016, 27, 571-580.	1.7	56
41	The transcardiac gradient of cardioâ€ <scp>microRNAs</scp> in the failing heart. European Journal of Heart Failure, 2016, 18, 1000-1008.	7.1	151
42	Effects of Milrinone on Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2016, 67, 2554-2556.	2.8	28
43	Norepinephrine transporter expression is inversely associated with glycaemic indices: a pilot study in metabolically diverse persons with overweight and obesity. Obesity Science and Practice, 2016, 2, 13-23.	1.9	3
44	Cardiac Implantable Electronic Devices and End-of-Life Care: An Australian Perspective. Heart Lung and Circulation, 2016, 25, 814-819.	0.4	3
45	Early Implantation of Primary Prevention Implantable Cardioverter Defibrillators for Patients with Newly Diagnosed Severe Nonischemic Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 992-998.	1.2	8
46	Severe left ventricular hypertrophy and marked cardiac fibrosis in Danon disease. International Journal of Cardiology, 2016, 221, 14-16.	1.7	7
47	Retained defibrillator leads following orthotopic heart transplantation. International Journal of Cardiology, 2016, 215, 87-89.	1.7	5
48	Reduction in peripheral vascular resistance predicts improvement in insulin clearance following weight loss. Cardiovascular Diabetology, 2015, 14, 113.	6.8	13
49	Left Ventricular Assist Device (LVAD) as a Bridge to Recovery for Tachycardia-Mediated Cardiomyopathy. Journal of Cardiac Surgery, 2015, 30, 871-873.	0.7	0
50	Clinical benefits of a specialised clinic for hypertrophic cardiomyopathy. Internal Medicine Journal, 2015, 45, 255-260.	0.8	5
51	Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. International Journal of Cardiology, 2015, 187, 227-228.	1.7	30
52	Clinical utility of invasive exercise hemodynamic evaluation in LVAD patients. Journal of Heart and Lung Transplantation, 2015, 34, 1635-1637.	0.6	13
53	Evaluating the Utility of Circulating Biomarkers of Collagen Synthesis in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2014, 7, 271-278.	3.9	42
54	Impaired Myocardial Oxygen Availability Contributes to Abnormal Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2014, 3, e001293.	3.7	47

#	Article	IF	CITATIONS
55	Determinants and implications of elevated soluble ST2 levels in heart failure. International Journal of Cardiology, 2014, 176, 1242-1243.	1.7	9
56	Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure. European Journal of Heart Failure, 2013, 15, 292-298.	7.1	27
57	Restoration of blood pressure control with pacemaker implantation in a patient with bradycardia and resistant hypertension: A case report. International Journal of Cardiology, 2013, 167, e38-e40.	1.7	5
58	Asystole Following Complex Partial Seizures. Heart Lung and Circulation, 2013, 22, 146-148.	0.4	2
59	Cardiac Complications of Thoracic Irradiation. Journal of the American College of Cardiology, 2013, 61, 2319-2328.	2.8	310
60	Exercise with a Twist: Left Ventricular Twist and Recoil in Healthy Young and Middle-Aged Men, and Middle-Aged Endurance-Trained Men. Journal of the American Society of Echocardiography, 2012, 25, 986-993.	2.8	22
61	Successful application of a PressureWire retrogradely across an ATS prosthetic aortic valve to diagnose constrictive pericarditis. Cardiovascular Revascularization Medicine, 2012, 13, 289-291.	0.8	0
62	Augmentation of left ventricular mechanics by recirculationâ€mediated AAV2/1–SERCA2a gene delivery in experimental heart failure. European Journal of Heart Failure, 2011, 13, 247-253.	7.1	51
63	Coadministration of Atorvastatin Prevents Nitroglycerin-Induced Endothelial Dysfunction and Nitrate Tolerance in Healthy Humans. Journal of the American College of Cardiology, 2011, 57, 93-98.	2.8	32
64	Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. Journal of Hypertension, 2011, 29, 553-564.	0.5	93
65	Delivery of Gene and Cellular Therapies for Heart Disease. Journal of Cardiovascular Translational Research, 2010, 3, 417-426.	2.4	11
66	Left Ventricular Ejection Fraction and Absence of ACE Inhibitor/Angiotensin II Receptor Blocker Predicts Appropriate Defibrillator Therapy in the Primary Prevention Population. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 696-704.	1.2	10
67	Hemodynamic Determinants of Myocardial B-Type Natriuretic Peptide Release. Hypertension, 2010, 56, 682-689.	2.7	64
68	Sympathetic Neural Adaptation to Hypocaloric Diet With or Without Exercise Training in Obese Metabolic Syndrome Subjects. Diabetes, 2010, 59, 71-79.	0.6	104
69	Observations of time-based measures of flow-mediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial function. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H939-H945.	3.2	29
70	Cardiac-Resynchronization Therapy. New England Journal of Medicine, 2010, 362, 177-179.	27.0	0
71	Primary Cardiac Lymphoma. Journal of the American College of Cardiology, 2010, 55, e23.	2.8	4
72	Intraoperative High-Density Global Mapping in Adult-Repaired Tetralogy of Fallot. Journal of the American College of Cardiology, 2010, 55, 2409-2411.	2.8	21

#	Article	IF	CITATIONS
73	Cardiac resynchronization therapy after atrioventricular node ablation for rapid atrial fibrillation in a heart transplant recipient with late allograft dysfunction. Journal of Heart and Lung Transplantation, 2010, 29, 704-706.	0.6	6
74	Prevalence of tricuspid regurgitation and pericardial effusions following pacemaker and defibrillator lead extraction. International Journal of Cardiology, 2010, 145, 593-594.	1.7	26
75	Bone Marrow-Derived Cells Contribute to Fibrosis in the Chronically Failing Heart. American Journal of Pathology, 2010, 176, 1735-1742.	3.8	94
76	Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. American Journal of Clinical Nutrition, 2009, 89, 27-36.	4.7	90
77	Age-related decline in stress responses of human myocardium may not be explained by changes in mtDNA. Mechanisms of Ageing and Development, 2009, 130, 742-747.	4.6	1
78	Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Therapy, 2008, 15, 1550-1557.	4.5	157
79	Utility of Myocardial Fibrosis and Fatty Infiltration Detected by Cardiac Magnetic Resonance Imaging in the Diagnosis of Arrhythmogenic Right Ventricular Dysplasia—A Single Centre Experience. Heart Lung and Circulation, 2008, 17, 478-483.	0.4	30
80	Aortic Valve Replacement for Aortic Stenosis During Orthotopic Cardiac Transplant. Annals of Thoracic Surgery, 2008, 86, 1979-1982.	1.3	16
81	Progression of Functional Mitral Regurgitation in Heart Failure Is Associated with Structural Remodeling and Worsened Outcomes. Journal of Cardiac Failure, 2008, 14, S32.	1.7	0
82	Myocardial Release of Stromal Derived Factor-1 and Stem Cell Factor and Cardiac Uptake of Progenitor Cells. Journal of Cardiac Failure, 2008, 14, S33.	1.7	0
83	Percutaneous Cardiac Recirculation-Mediated Gene Transfer of an Inhibitory Phospholamban Peptide Reverses Advanced Heart Failure in Large Animals. Journal of the American College of Cardiology, 2007, 50, 253-260.	2.8	136
84	Cardiac resynchronisation therapy for heart failure. Internal Medicine Journal, 2006, 36, 114-123.	0.8	4
85	The successful treatment of primary cardiac lymphoma with a dose-dense schedule of rituximab plus CHOP. Annals of Oncology, 2006, 17, 176-177.	1.2	30
86	Biventricular pacing in heart failure: a review. Expert Review of Cardiovascular Therapy, 2006, 4, 97-109.	1.5	2
87	Tolerance to ischemia and hypoxia is reduced in aged human myocardium. Journal of Thoracic and Cardiovascular Surgery, 2000, 120, 660-667.	0.8	103
88	Coenzyme Q <sub>10</sub> improves the tolerance of the senescent myocardium to aerobic and ischemic stress: Studies in rats and in human atrial tissue. BioFactors, 1999, 9, 291-299.	5.4	50
89	Repair Of postmyocardial infarct ventricular free wall rupture using an onlay pericardial patch. Heart, Lung and Circulation, 1999, 8, 110-114.	0.1	0
90	Response of the Human Myocardium to Hypoxia and Ischemia Declines with Age: Correlation with Increased Mitochondrial DNA Deletions. Annals of the New York Academy of Sciences, 1998, 854, 489-490.	3.8	0